Skip to main content
. Author manuscript; available in PMC: 2021 Apr 28.
Published in final edited form as: J Am Coll Cardiol. 2020 Apr 28;75(16):1956–1974. doi: 10.1016/j.jacc.2020.02.056

CENTRAL ILLUSTRATION. Diversity of Physiologic Effects of SGLT2i and GLP1RA.

CENTRAL ILLUSTRATION

Increasing evidence supports the role of both SGLT2i and GLP1RA in reducing major adverse cardiac events and progression of renal disease while increasing weight loss and reducing blood pressure. SGLT2i accomplish this primarily via hemodynamic effects, whereas GLP1RAs have stronger anti-atherogenic effects.GLP1RA = glucagon-like peptide 1 receptor agonist; MACE = major adverse cardiac events; SGLT21 = sodium glucose cotransporter 2 inhibitor.